Hepatitis vaccination til patienter med HIV infektion. Betydning af adjuverende interleukin-2

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002171-33-DK

Enrollment

Registered

2005-07-06

Start date

2005-09-14

Completion date

Unknown

Last updated

2016-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patienter med Hiv infektion har øget risiko for hepatitis A og hepatitis B. Sundhedsmyndigheder anbefaler vaccination. Effekt er imidlertid mindre end for raske personer. Forsøget tester om adjuverende interleukin-2 øger effekt.

Interventions

Trade Name: Twinrix Product Name: Twinrix Pharmaceutical Form: Injection* Trade Name: Proleukin Product Name: Proleukin Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV infektion Alder > 18 år Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Serologisk dokumentation af tidligere infektion med hepatitis A eller hepatitis B

Design outcomes

Primary

Measure	Time frame
Main Objective: Effekt af hepatit vaccination hos hiv patienter;Secondary Objective: ;Primary end point(s): Antistof respons efter 3 injektioner Twinrix	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026